U.S., Aug. 8 -- ClinicalTrials.gov registry received information related to the study (NCT07752758) titled 'Ezetimibe for Arrhythmia Recurrence After AF Ablation' on July 30.
Brief Summary: This single-center, prospective, single-blind randomized controlled pilot trial aims to explore whether oral ezetimibe can reduce the 6-month recurrence rate of atrial tachyarrhythmia after catheter ablation in patients with persistent atrial fibrillation. A total of 120 eligible patients will be randomized at a 1:1 ratio into the ezetimibe group and the control group within 24 hours after ablation. Stratified randomization based on body mass index (BMI) and left atrial diameter will be performed via an interactive web response system (IWRS). This study...